Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | STK4 | Q13043 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20430476 | 0.86 | MELK (0.40) | MTOR | |
| SCHEMBL31439307 | 0.86 | MTOR (0.47) | MTORAXLPIK3CAPRKDCSTK4 | |
| SCHEMBL15747836 | 0.86 | MTOR (0.47) | MTORAXLPIK3CAPRKDCSTK4 | |
| SCHEMBL31439343 | 0.83 | MTOR (0.42) | MTORPIK3CA | |
| SCHEMBL15747832 | 0.83 | MTOR (0.42) | MTORPIK3CA | |
| SCHEMBL14978610 | 0.83 | MTOR (0.42) | MTORAXLPIK3CAPRKDCSTK4 | |
| SCHEMBL16086154 | 0.83 | MTOR (0.43) | MTORAXLPIK3CA | |
| SCHEMBL18807465 | 0.80 | MTOR (0.52) | MTOR | |
| SCHEMBL14978580 | 0.80 | DYRK1A (0.51) | MTOR | |
| SCHEMBL15615899 | 0.74 | MTOR (0.46) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719697-B1 | PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| EP-2781520-B1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2016-05-04 | — | — | EP | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2781520-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071698-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | 山东轩竹医药科技有限公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | MTOR, RICTOR, AKT3 | MTOR 1/4885AXL 1074/4885PIK3CA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.